Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Back Pain, Chronic Low Back Pain, Internal Disc Disruption, Degenerative Disc Disease
Interventions: BIOSTAT BIOLOGX, Saline; Biological · Drug
Lead sponsor: Spinal Restoration, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 17 more

Conditions: Healthy
Interventions: Canagliflozin (JNJ-28431754), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy
Interventions: DSP-1053, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diabetes Mellitus
Interventions: Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 12 more

Conditions: Cystic Fibrosis
Interventions: VX-659/TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 48
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more

Conditions: Solid Tumor
Interventions: Trabectedin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Miami, Florida • Charlotte, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Treatment Resistant Depressive Disorder
Interventions: Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more

Conditions: Arthritis, Rheumatoid
Interventions: PD 0360324, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Peoria, Arizona • Daytona Beach, Florida • Port Orange, Florida + 5 more

Conditions: Chronic Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 65 Years and older
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 102
States / cities: Columbiana, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 99 more

Conditions: Neuroblastoma
Interventions: Ceritinib, dasatinib, sorafenib, vorinostat, DFMO; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: Up to 22 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2035
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more

Conditions: Cocaine-Related Disorders
Interventions: Low Dose Modafinil, High Dose Modafinil, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: JNJ-67484703, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Anniston, Alabama • Orland Park, Illinois

Conditions: Obesity
Interventions: TTP435, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Augusta, Georgia + 6 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: Suzetrigine, Placebo (matched to SUZ); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 71 more

Conditions: Chemotherapy Induced Nausea and Vomiting
Interventions: dronabinol, ondansetron, dronabinol/ondansetron, placebo; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 43
States / cities: Tucson, Arizona • Anaheim, California • Fountain Valley, California + 37 more

Conditions: Knee Osteoarthritis, Pain Management
Interventions: bupivacaine liposome injectable suspension, Bupivacaine Hydrochloride; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 6
States / cities: Little Rock, Arkansas • Pasadena, California • Dayton, Ohio + 3 more

Conditions: Diabetic Peripheral Neuropathy, B Vitamin Deficiency
Interventions: Metanx, Placebo; Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 25
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 21 more

Conditions: Any Non-traumatic Musculoskeletal Condition
Interventions: Nudge intervention; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ototoxicity
Interventions: DB-020, Placebo; Drug
Lead sponsor: Decibel Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Miami, Florida • Kansas City, Kansas • Lake Success, New York + 1 more

Conditions: Kidney Transplantation
Interventions: hOKT3, Oral Cyclosporine, IV Cyclosporine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 20 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Pain, Postoperative
Interventions: Local anesthesia at incision site, Sham QL, Sham Local, QL; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis, Knee
Interventions: Ropivacaine Continuous Infusion, Ropivacaine Intermittent Bolus, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more

Conditions: Metabolic Syndrome, Normal Cognition
Interventions: Ketone Ester drink, Placebo: isocaloric dextrose drink; Dietary Supplement
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Modafinil Treatment for Cocaine-Dependent Individuals

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty

The Nutritional Benefits of Metanx in Patients With Diabetic Peripheral Neuropathy (MEDIAN)

Testing a Brief Reassurance Message Before a Musculoskeletal Clinic Visit

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

A Study To Test An Anti-Rejection Therapy After Kidney Transplantation

The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy

A Study to Compare the Effectiveness of Adductor Canal Pain Catheters Following Total Knee Arthroplasty

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older